VIT-2763
Based on 8 publication(s) in Google Scholar
VIT-2763, an oral ferroportin inhibitor, inhibits hepcidin binding to ferroportin and blocks iron efflux. VIT-2763 has the potential in the treatment of β-thalassemia.
For research use only. We do not sell to patients.
- Purity : 99.93%
- CAS No.: 2095668-10-1
- Formula: C21H21FN6O2
- Molecular Weight:408.43
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) VIT-2763
More- Cell. 2025 Oct 30;188(22):6335-6354.e26. [Abstract]
- Cell Death Discov. 2026 Jul 31.
- Development. 2023 Oct 15;150(20):dev201690. [Abstract]
- PLoS Negl Trop Dis. 2025 Dec 11;19(12):e0013815. [Abstract]
- FEBS Lett. 2026 Feb 28. [Abstract]
- bioRxiv. 2026 Aug 15.
- bioRxiv. 2025 Nov 26.
- bioRxiv. 2025 Apr 26:2025.04.23.650120.
Customer Validation & Images
-
RT-PCR
-
WB
-
Cell Proliferation/Viability Assay
-
IF
-
Bio/Physico-chemical Assay
Biological Activity
Description
In Vitro
VIT-2763 dose dependently reduces the fluorescence polarization signal, indicating that VIT-2763 displaces TMR-hepcidin from ferroportin (IC50 of 24 ± 13 nM)[1].
VIT-2763 induces BLA reporter gene activity with an average EC50 of 140 ± 50 nM, as a consequence of increasing intracellular iron concentrations caused by blocked iron export in HEK293 cells[1].
VIT-2763 (100 nM) triggers ubiquitination and subsequent internalization and degradation of ferroportin[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:J774 cells.
-
Concentration:100 nM.
-
Incubation Time:10, 20, 40, 60, or 120 minutes.
-
Result:Induced ferroportin internalization and ubiquitination.
In Vivo
VIT-2763 did not change the total liver iron[1].
VIT-2763 (30, 100 mg/kg, orally twice daily for 36 days) significantly corrects anemia and improved RBC parameters in Hbbth3/+ mice. VIT-2763 decreases the percentage of ROS-positive RBCs in Hbbth3/+ mice from 67% to 30%[1].
VIT-2763 decreases apoptosis and extends the life span of RBCs in Hbbth3/+ mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hbbth3/+ mice[1].
-
Dosage:30, 100 mg/kg.
-
Administration:Orally twice daily for 36 days.
-
Result:Significantly decreased serum iron levels by 77% (30 mg/kg) and 84% (100 mg/kg),
Significantly increased Hb levels (as of day 8 of treatment), RBC counts, mean corpuscular Hb concentration (MCHC), and significantly lowered reticulocyte counts, mean corpuscular Hb (MCH), mean corpuscular volume (MCV), and RBC distribution width (RDW) in Hbbth3/+ mice, as compared with the Hbbth3/+ vehicle group.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2095668-10-1
-
Appearance Solid
-
Molecular Weight 408.43
-
Formula C21H21FN6O2
-
Color Off-white to light yellow
-
SMILES
O=C(C1=COC(CCNCCC2=NC3=CC=CC=C3N2)=N1)NCC4=NC=CC=C4F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Cell
2025 Oct 30;188(22):6335-6354.e26. PMID: 40907490 -
-
Development
Heme-deficient primitive red blood cells induce HSPC ferroptosis by altering iron homeostasis during zebrafish embryogenesis. [Abstract]2023 Oct 15;150(20):dev201690. PMID: 37227070
VIT-2763 purchased from MedChemExpress. Usage Cited in: Development. 2023 Oct 15;150(20):dev201690. [Abstract]
Expression of HSPC marker gene runx1 in control, alas2−/− and alad−/− with or without VIT2763 treatment at 36 hpf examined by WISH. The AGM regions for marker gene-positive cell counting are denoted by red arrowheads.
-
PLoS Negl Trop Dis
The phytochemical arbutin exerts potent anti-Toxoplasma effects through activation of cell-autonomous defense mechanisms while attenuating inflammation. [Abstract]2025 Dec 11;19(12):e0013815. PMID: 41379884
VIT-2763 purchased from MedChemExpress. Usage Cited in: PLoS Negl Trop Dis. 2025 Dec 11;19(12):e0013815. [Abstract]
The levels of LIP were found to increase after VIT-2763 (20 μM, 2 h) treatment, and the relative intracellular parasite numbers increased correspondingly, suggesting that iron restriction is a crucial defense mechanism against Tg RH infection in both immune and non-immune cells.
-
FEBS Lett
Transferrin receptor 1-mediated iron uptake supports thermogenic activation in human cervical-derived adipocytes. [Abstract]2026 Feb 28. PMID: 41761895
VIT-2763 purchased from MedChemExpress. Usage Cited in: FEBS Lett. 2026 Feb 28. [Abstract]
The effect of ferroportin inhibitor (VIT-2763) on oxygen consumption and protein expression of mitochondrial complex subunits in human ex vivo differentiated subcutaneous (SubQ) and deep cervical (DeepC)-derived adipocytes.
VIT-2763 purchased from MedChemExpress. Usage Cited in: FEBS Lett. 2026 Feb 28. [Abstract]
The effect of ferroportin inhibitor (VIT-2763) on oxygen consumption and protein expression of mitochondrial complex subunits in human ex vivo differentiated subcutaneous (SubQ) and deep cervical (DeepC)-derived adipocytes.
-
VIT-2763 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Aug 15.
Cell viability of primary osteoblasts from wild-type (WT) and hemizygous βIVSII-654 knock-in thalassemia (B654) mice after exposure to 5 µM and 20 µM VIT-2763 for 4 days.
VIT-2763 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Aug 15.
Immunofluorescence staining images of Ferroportin-1 protein in primary osteoclasts derived from wild-type (WT) bone marrow cells after 3 days of treatment with 20 µM VIT-2763 (captured via confocal microscopy). Scale bar: 20 μm (40× magnification).
-
-
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (244.84 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4484 mL | 12.2420 mL | 24.4840 mL | 61.2100 mL |
| 5 mM | 0.4897 mL | 2.4484 mL | 4.8968 mL | 12.2420 mL | |
| 10 mM | 0.2448 mL | 1.2242 mL | 2.4484 mL | 6.1210 mL | |
| 15 mM | 0.1632 mL | 0.8161 mL | 1.6323 mL | 4.0807 mL | |
| 20 mM | 0.1224 mL | 0.6121 mL | 1.2242 mL | 3.0605 mL | |
| 25 mM | 0.0979 mL | 0.4897 mL | 0.9794 mL | 2.4484 mL | |
| 30 mM | 0.0816 mL | 0.4081 mL | 0.8161 mL | 2.0403 mL | |
| 40 mM | 0.0612 mL | 0.3061 mL | 0.6121 mL | 1.5303 mL | |
| 50 mM | 0.0490 mL | 0.2448 mL | 0.4897 mL | 1.2242 mL | |
| 60 mM | 0.0408 mL | 0.2040 mL | 0.4081 mL | 1.0202 mL | |
| 80 mM | 0.0306 mL | 0.1530 mL | 0.3061 mL | 0.7651 mL | |
| 100 mM | 0.0245 mL | 0.1224 mL | 0.2448 mL | 0.6121 mL |
VIT-2763 Related Classifications
HY-112220 Related Classifications
Powered by Bioz